secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001558370-23-004698
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris extends former CFO Frank Ruffo's consulting term to June 30, 2023 with $12,500 monthly fee
--------------------------------------------------------------------------------

- Consulting term extended from March 3, 2023 through June 30, 2023.
- Monthly consulting fee set at $12,500 for services rendered during the term.
- No outstanding equity awards will vest after March 2, 2023; vesting ceased on that date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023004698/0001558370-23-004698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023004698/acrs-20230323x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-004698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer